Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2023 Apr 14

PMID 37057033

Authors

Niki Gavrielatou

Ioannis Vathiotis

Thazin Nwe Aung

Saba Shafi

Sneha Burela

Aileen I Fernandez

Myrto Moutafi

Barbara Burtness

Panagiota Economopoulou

Maria Anastasiou

Periklis Foukas

Amanda Psyrri

David L Rimm

Affiliations

Soon will be listed here.

Abstract

Significance: In the current study, DSP revealed the positive association of B2M expression in the tumor compartment with immunotherapy outcomes in R/M HNSCC.

Citing Articles

Digital Spatial Profiling identifies distinct patterns of immuno-oncology-related gene expression within oropharyngeal tumours in relation to HPV and p16 status.

Brooks J, Zheng Y, Hunter K, Willcox B, Dunn J, Nankivell P Front Oncol. 2024; 14:1428741.

PMID: 39328208 PMC: 11424609. DOI: 10.3389/fonc.2024.1428741.

Spatial proteomics: unveiling the multidimensional landscape of protein localization in human diseases.

Wu M, Tao H, Xu T, Zheng X, Wen C, Wang G Proteome Sci. 2024; 22(1):7.

PMID: 39304896 PMC: 11416001. DOI: 10.1186/s12953-024-00231-2.

Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer.

Cho U, Im S, Park H J Pathol Transl Med. 2024; 58(2):49-58.

PMID: 38389279 PMC: 10948248. DOI: 10.4132/jptm.2024.01.31.

Multiplex protein imaging in tumour biology.

de Souza N, Zhao S, Bodenmiller B Nat Rev Cancer. 2024; 24(3):171-191.

PMID: 38316945 DOI: 10.1038/s41568-023-00657-4.

A Spatial Transcriptome Reveals Changes in Tumor and Tumor Microenvironment in Oral Cancer with Acquired Resistance to Immunotherapy.

Iwasa Y, Nakajima T, Hori K, Yokota Y, Kitoh R, Uehara T Biomolecules. 2023; 13(12).

PMID: 38136558 PMC: 10742283. DOI: 10.3390/biom13121685.

References

Garrido F, Ruiz-Cabello F, Aptsiauri N . Rejection versus escape: the tumor MHC dilemma. Cancer Immunol Immunother. 2017; 66(2):259-271. PMC: 11028748. DOI: 10.1007/s00262-016-1947-x. View

Beechem J . High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research. Methods Mol Biol. 2019; 2055:563-583. DOI: 10.1007/978-1-4939-9773-2_25. View

Sade-Feldman M, Jiao Y, Chen J, Rooney M, Barzily-Rokni M, Eliane J . Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017; 8(1):1136. PMC: 5656607. DOI: 10.1038/s41467-017-01062-w. View

Haddad R, Seiwert T, Chow L, Gupta S, Weiss J, Gluck I . Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022; 10(2). PMC: 8883256. DOI: 10.1136/jitc-2021-003026. View

Schumacher T, Scheper W, Kvistborg P . Cancer Neoantigens. Annu Rev Immunol. 2018; 37:173-200. DOI: 10.1146/annurev-immunol-042617-053402. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Gavrielatou N, Doumas S, Economopoulou P, Foukas P, Psyrri A . Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020; 84:101977. DOI: 10.1016/j.ctrv.2020.101977. View

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

10.

. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536):576-82. PMC: 4311405. DOI: 10.1038/nature14129. View

11.

Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y . HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006; 66(18):9281-9. DOI: 10.1158/0008-5472.CAN-06-0488. View

12.

Perez Sayans M, Chamorro Petronacci C, Lorenzo Pouso A, Padin Iruegas E, Blanco Carrion A, Suarez Penaranda J . Comprehensive Genomic Review of TCGA Head and Neck Squamous Cell Carcinomas (HNSCC). J Clin Med. 2019; 8(11). PMC: 6912350. DOI: 10.3390/jcm8111896. View

13.

Martinez-Morilla S, Villarroel-Espindola F, Wong P, Toki M, Aung T, Pelekanou V . Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. Clin Cancer Res. 2021; 27(7):1987-1996. PMC: 8026677. DOI: 10.1158/1078-0432.CCR-20-3340. View

14.

Meissner M, Reichert T, Kunkel M, Gooding W, Whiteside T, Ferrone S . Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res. 2005; 11(7):2552-60. DOI: 10.1158/1078-0432.CCR-04-2146. View

15.

Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. View

16.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018; 81:45-51. PMC: 6563923. DOI: 10.1016/j.oraloncology.2018.04.008. View

17.

Chen C, Su C, Chien C, Huang C, Chuang H, Fang F . Overexpression of beta2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion. Br J Cancer. 2008; 99(9):1453-61. PMC: 2579697. DOI: 10.1038/sj.bjc.6604698. View

18.

Emancipator K, Huang L, Aurora-Garg D, Bal T, Cohen E, Harrington K . Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol. 2020; 34(3):532-541. DOI: 10.1038/s41379-020-00710-9. View

19.

Seiwert T, Burtness B, Mehra R, Weiss J, Berger R, Eder J . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17(7):956-965. DOI: 10.1016/S1470-2045(16)30066-3. View

20.

Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View